The Nasdaq-to-OTCQB transition is a material negative catalyst that will reduce liquidity and institutional interest. Monitor for FDA feedback in mid-2026 as the only near-term binary event. The $22.2M cash position provides runway into late 2026, but the OTCQB listing makes follow-on financing more dilutive.
RVPH drugs
RVPH drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 14 $0.3900entry
- T+1 · 6mo ago 0.00%α −0.01% · $0.3900
- T+5 · 6mo ago +7.55%α +8.26% · $0.4194
- T+20 · 5mo ago +75.36%α +76.22% · $0.6839
- T+60 · 3mo ago +10.33%α +6.74% · $0.4303
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Reviva Pharmaceuticals reported Q1 2026 net loss of $3.2M ($0.46/share), narrower than the year-ago $6.4M loss ($2.61/share), but the EPS of -$0.46 missed the consensus estimate of -$0.29 by 58.6%. The company is advancing its brilaroxazine program with FDA feedback expected mid-2026 and RECOVER-2 Phase 3 enrollment in Q3 2026, but its stock is transitioning from Nasdaq to OTCQB effective May 14, 2026, which severely limits liquidity and access to capital.
Key Financial Metrics
Key Facts
- Q1 2026 net loss of $3.2M ($0.46/share) vs $6.4M ($2.61/share) in Q1 2025
- EPS of -$0.46 missed consensus estimate of -$0.29 by 58.6%
- Cash and equivalents $22.2M as of March 31, 2026, up from $14.4M at year-end 2025
- Common stock transitioning from Nasdaq to OTCQB effective May 14, 2026
- Completed $10M public equity offering in March 2026
- FDA feedback on new brilaroxazine form expected mid-2026; RECOVER-2 Phase 3 enrollment expected Q3 2026
Financial Impact
EPS miss of 58.6% vs consensus; net loss improved YoY but still significant burn rate of ~$3.2M/quarter
Risk Factors
- OTCQB listing severely limits liquidity and institutional ownership
- Cash burn of ~$3.2M/quarter with no revenue; may require dilutive financing
- FDA feedback on brilaroxazine form is binary and could delay RECOVER-2 trial
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294478 |
Track record
12 reports on RVPH
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +22.98% at T+20 after the Jul 10, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 3/10 No price data
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.3400 Now $0.3504 +3.07% settles Feb 11
- Nov 9, 20267d ago DEF 14A Neutral 4/10 Entry $0.3521 Now $0.3504 −0.47% settles Feb 8
- Aug 12, 202613w ago Press Release Neutral 4/10 Entry $0.3521 to $0.3521 Now $0.3504 −0.47% · 0.00% +5.48% vs SPY
- Jul 10, 202618w ago 25-NSE Bearish 7/10 Entry $0.6200 to $0.5000 Now $0.3504 +43.48% ▲ +19.35% +22.24% vs SPY
- May 13, 202626w ago Press Release Bearish 7/10 Viewing Entry $0.3900 to $0.4303 Now $0.3504 +10.14% ▼ −10.33% −6.74% vs SPY
- May 13, 202626w ago 8-K Bearish 8/10 Entry $0.3521 to $0.4775 Now $0.3504 +0.47% ▼ −35.62% −31.19% vs SPY
- Apr 15, 202630w ago 8-K Neutral 5/10 Entry $0.8900 to $0.5731 Now $0.3504 −60.62% ▼ −35.61% −43.74% vs SPY
- Mar 30, 202633w ago Press Release Mixed 6/10 Entry $0.6600 to $0.6000 Now $0.3504 −46.90% ▼ −9.09% −25.58% vs SPY
- Mar 18, 202634w ago Press Release Bearish 6/10 Entry $0.8300 to $0.7000 Now $0.3504 +57.78% ▲ +15.66% +30.01% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers